Triple Incretin Combination Outperforms Single GLP-1 Drug for Fatty Liver Disease in Mice

Mice were fed a high-fat, high-fructose, high-cholesterol diet for 36 weeks to develop NASH with fibrosis, then treated for 8 weeks. Low-dose glucagon or GIP alone did not affect body weight, liver fat, or liver damage scores. But when combined with GLP-1 receptor activation, both glucagon and GIP provided additional benefits.

The triple combination (GLP-1 + glucagon + GIP) and a dual GLP-1/glucagon peptide both significantly reduced the NAFLD activity score more than high-dose liraglutide. This happened at comparable levels of weight loss, meaning the extra liver improvement came from the hormones themselves, not just from losing weight.

This supports the idea that multi-receptor agonists targeting two or three gut hormone receptors could be more effective for NASH than GLP-1 drugs alone.

NASH is a leading cause of liver disease with limited treatment options. Current GLP-1 drugs help partly through weight loss, but this study shows that adding glucagon and GIP receptor activation provides liver benefits beyond what weight loss alone can explain.

This research supports the development of multi-agonist drugs like tirzepatide and experimental triple agonists for liver disease.

This was a mouse study using a diet-induced NASH model, which does not perfectly replicate human NASH. The 8-week treatment period may not capture longer-term effects or safety concerns.

The individual agonist doses were low, which may explain why they had no effect alone. Higher doses might have shown different results.